Health Condition 1: N309- Cystitis, unspecified
Conditions
Interventions
Intervention1: Cystone GNX tablet: This clinical study is an open label, two arm, randomized, comparative clinical study designed to evaluate the efficacy and safety of Cystone GNX tablet in compariso
Sponsors
The Himalaya Drug Company
Eligibility
Inclusion criteria
Inclusion criteria: Adult male and female subjects aged >=18 to Cystitis as diagnosed by urine culture more than 105 CFU/mL Subjects willing to sign informed consent and follow the study procedure. Subjects who has not participated in any similar kind of clinical study in the last one month.
Exclusion criteria
Exclusion criteria: History of neurogenic bladder, pelvic irradiation or chemical cystitis, presence of urethral, pelvic, or rectal carcinoma, benign or malignant bladder tumors, tuberculous cystitis Kidneys Infection Pre-existing urolithiasis condition Pre-existing systemic disease: cardiac, neurological, renal or hepatic dysfunction. Antibacterial drug therapy during the previous 72 hours Patients with suspected or confirmed prostatitis Patients with renal transplantation or ileal loops History of urinary tract structural abnormalities. Any recent history of trauma to the pelvis or urinary tract. Pregnant & breast-feeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjects demonstrating percentage improvement in the terms of efficacy parameters such as laboratory and clinical parameters from baseline to end of study.Timepoint: day 14 and 28. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety evaluation through Incidence of adverse events during the study period. Compliance of the subject to the study medication Timepoint: day 14 and 28. | — |
Countries
India
Contacts
Public ContactDr Palaniyamma
The Himalaya Drug Company
Outcome results
None listed